Merck & Co., Inc.
147.53USD
-0.9300 (-0.63%)
Computing valuation metrics…
Valuation
P/E (TTM)
114.71x
P/E (Forward)
15.45x
EV/EBITDA
14.31x
EV/Revenue
6.21x
P/S (TTM)
5.47x
P/B
8.68x
FCF Yield
4.41%
Dividend Yield
2.29%
Gross Margin
72.97%
Operating Margin
-0.24%
Net Margin
4.77%
Peer Comparison — Drug Manufacturers - General
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | $363.98B | 114.71x | 14.31x | 4.41% | 5.07% | 2.29% |
| LLYEli Lilly and Company | $1.00T | 37.75x | 25.12x | 1.10% | 47.70% | 0.62% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $643.64B |
| 31.02x |
| 19.41x |
| 2.62% |
| 6.60% |
| 1.99% |
| ABBVAbbVie Inc. | $443.39B | 71.08x | 16.50x | 3.80% | 10.20% | 2.78% |
| NVSNovartis AG | $261.31B | 20.77x | 13.12x | 4.55% | 0.80% | 3.44% |
| AMGNAmgen Inc. | $211.53B | 24.33x | 14.76x | 4.09% | 9.50% | 2.56% |
| GILDGilead Sciences, Inc. | $180.60B | — | 13.83x | 5.41% | 10.20% | 2.24% |
| PFEPfizer Inc. | $158.39B | 36.57x | 8.44x | 7.88% | 2.60% | 6.05% |
| BMYBristol-Myers Squibb Company | $131.57B | 14.19x | 8.75x | 6.17% | 5.70% | 3.90% |